Review article: inflammatory bowel disease--empowering the patient and improving outcome

A Robinson1

  • 1Department of Gastrointestinal Sciences, Hope Hospital, Salford, UK. andrew.robinson@srht.nhs.uk

Insights

Guided self-management empowers patients with inflammatory bowel disease (IBD) to actively participate in their care. This approach can improve treatment adherence and reduce healthcare utilization for chronic disease management.

Area of Science:

  • Gastroenterology
  • Chronic Disease Management
  • Health Psychology

Background:

  • Inflammatory bowel disease (IBD) management relies heavily on specialist clinician visits, leading to patient disempowerment and disengagement.
  • Current appointment systems are inefficient for relapsing/remitting conditions, causing patient inconvenience and noncompliance.
  • Self-care is a fundamental aspect of health, with formalized guided self-management showing promise.

Purpose of the Study:

  • To explore the effectiveness and patient acceptability of guided self-management strategies for inflammatory bowel disease.
  • To identify barriers and facilitators to implementing guided self-management in IBD care.
  • To assess the impact of guided self-management on health service utilization and patient outcomes.

Main Methods:

  • Review of recent studies on guided self-management in stable ulcerative colitis.
  • Analysis of patient and clinician perspectives on shared decision-making in chronic disease management.
  • Exploration of potential barriers, including clinician reluctance and patient preferences.

Main Results:

  • Guided self-management in stable ulcerative colitis patients led to reduced healthcare service use.
  • Patients experienced faster access to treatment and high acceptability of self-management approaches.
  • No compromise in health outcomes was observed in studies of guided self-management.

Conclusions:

  • Guided self-management offers a promising approach to improve inflammatory bowel disease care by enhancing patient compliance and engagement.
  • Addressing barriers, such as clinician hesitancy and patient preferences, is crucial for successful implementation.
  • Further research is needed to confirm long-term outcomes, but initial indications suggest improved patient responsibility and well-being.

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...